Brief: BrainsWay Receives New FDA Clearance For Treating Depression And Anxious Depression
29/08/2022 13:11
Aug 29 (Reuters) - Brainsway Ltd BWAY.TA :
* BRAINSWAY RECEIVES NEW FDA CLEARANCE FOR TREATING
DEPRESSION AND
ANXIOUS DEPRESSION
* BRAINSWAY - WILL BE IMPLEMENTING TRAINING PROGRAM IN
COMING
MONTHS TO EDUCATE CUSTOMERS ON USING DEEP TMS H7 COIL TO TREAT
DEPRESSION WITHIN NEW FDA CLEARANCE
Source text for Eikon: ID:nGNX5bY5WQ
Further company coverage: BWAY.TA
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Brainsway
See all newsBrief: Brainsway Presents Positive Data From Largest Real-World Study Of Deep Tms™ In Patients With Comorbid Ptsd And Major Depressive Disorder
Brief: Brainsway Announces Minority-Stake Investment In Hopemark Health
Brief: Brainsway Announces New Minority-Stake Investment In Canadian Provider, Brainstim Health Inc.
Brief: Brainsway Announces Change In ADS-To-Ordinary Share Ratio
Brief: BrainsWay Announces FDA Approval of Neurolief’s Proliv™Rx Neuromodulation System for Major Depressive Disorder (MDD)